Phentermine is a sympathomimetic amine [derived from amphetamine] initially approved by the FDA in 1959 for the treatment of obesity. Its usage in the treatment of obesity was considered ideal due to the fact that phentermine suppressed appetite through central modulation of norepinephrine, and peripherally mobilized fat stores through catecholaminergic upregulation. That said, in the …
Phentermine is an anorectic medication utilized principally for the short-term treatment of obesity as an adjunct to caloric restriction, dietary modifications, and physical exercise. It is formally classified as a psychostimulant due to the fact that it increases mental and physical arousal [via sympathomimetic mechanisms]. Specifically, phentermine facilitates central and peripheral catecholamine release (primarily of …
Phentermine is a natural monoamine alkaloid derivative that was initially approved by the United States FDA in 1959 as an anorectic (appetite suppressant) for the treatment of obesity. It was popularized throughout the early 1970s under the brand name medication “Fastin,” marketed by King Pharmaceuticals. In the late 1990s phentermine was discontinued from pharmaceutical circulation, …
Qsymia is a weight loss drug engineered by the California-based pharmaceutical company Vivus Inc. It was initially approved by the FDA in 2012 for weight reduction among adults with BMIs (body mass indexes) exceeding 30 kg/m² as an adjunct to interventions such as caloric restriction, dietary modification, and regular exercise. Qsymia is also approved for …